Skip Ribbon Commands
Skip to main content
Menu
Dr Ong Shin Yeu

Dr Ong Shin Yeu

MD, MRCP (UK), MSE, FRCPath (Haematology)

Consultant

Singapore General Hospital

Specialty: Haematology

Sub-specialties: Lymphoma

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukemia (CML), Deep Vein Thrombosis, Deep Vein Thrombosis, essential thrombocythemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelofibrosis, Polycythemia Vera, Thalassaemia.

Clinical Appointments

  • Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Consultant Haematology Singapore General HospitalSingapore General Hospital

Profile

​Dr Ong graduated from Duke University, Durham, USA, with a Bachelor of Science in Biomedical and Electrical Engineering in 2004 with a Summa Cum Laude and completed a Masters of Science in Biomedical Engineering at Johns Hopkins University, Baltimore, USA in 2006 with a thesis entitled the hepatic differentiation potential of human mesenchymal stem cells. She then worked for 2.5 years as a research engineer, developing wound dressing and coordinating clinical trials with the USA Naval Research Medical Center before joining Duke-NUS Graduate Medical School and graduating in 2012 with the Singhealth Seah Cheng Siang Gold Medal, awarded to the best student in Internal Medicine. After completing Junior Residency in Internal Medicine and Senior Residency in Haematology, she is now a Consultant since November 2020 with a subspecialty focus on Lymphoma and Flow Cytometry. She has obtained her membership from the Royal College of Physicians of the United Kingdom in 2014 and Royal College of Pathologists of the United Kingdom in 2017.  She is actively involved in investigator and pharmaceutical sponsored trials for lymphoma and myeloma and published several papers in peer reviewed journals. In 2020, Dr Ong received the HMDP award for a fellowship in Personalised Immunotherapy in Stanford University, USA. Her career goals are to improve treatment outcomes for lymphoma and to improve flow cytometry diagnostics.

Education

Professional Appointments and Committee Memberships

  • ​Clinical Tutor – Yong Loo Lin School of Medicine, NUS
  • Clinical Assistant Professor – Duke-NUS Medical School 


Awards

  • ​Singapore Health Manpower Development Plan Award (2020)
  • Singhealth Service with a Heart Award (2019)
  • Singhealth Outstanding Resident Award (2016)
  • Singhealth Service with a Heart Award (2016)
  • Singhealth Seah Cheng Siang Gold Medal in Medicine, Singapore (2012)
  • Duke-NUS Shaw Foundation Scholarship (2008)


Research Interests

Publications

  • ​Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, et al. No association between ECSIT germline mutations and hemophagocytic  lymphohistiocytosis in natural killer/T-cell lymphoma. Vol. 106, Haematologica. 2021. p. 1737–9. 
  • Lee W-HS, Ye Z, Cheung AMS, Goh YPS, Oh HLJ, Rajarethinam R, et al. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther [Internet]. 2021;20(9):1702–12. 
  • Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150. 
  • Ong SY, Tan CW, Ramya V, Malik AA, Lee XH, Hwang JCC, et al. Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol [Internet]. 2021 Mar;100(3):645–51. 
  • Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143.
  • Lin G-W, Xu C, Chen K, Huang H-Q, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020 Feb;21(2):306–16.
  • Ong SY, Phipps C, Nagarajan C, Tang T, Lim ST, Goh YT, et al. Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 225–7. 
  • Ong SY, Phipps C, Kaur H, Tan L, Lee YS. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma. Vol. 48, Annals of the Academy of Medicine, Singapore. Singapore; 2019. p. 298–300. 
  • Ong SY, Ng HJ. Howell-Jolly bodies in systemic amyloidosis. Vol. 108, International journal of hematology. Japan; 2018. p. 119–20. 
  • Ong SY, Li S-T, Wong GC, Ho AYL, Nagarajan C, Ngeow J. Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of cases in Asia. Vol. 9, Leukemia research reports. 2018. p. 54–7. 
  • Ong SY, Chin YA, Than H, Tan CW, Yap ES, Wong WH, et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence. Ann Hematol. 2017;96(3):525–7. 
  • Ong SY, Ho LP, Yeo PM, Ng HJ, Ang AL. Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia  with t(8;21). Vol. 106, International journal of hematology. Japan; 2017. p. 149–50. 
  • Bari S, Seah KKH, Poon Z, Cheung AMS, Fan X, Ong S-Y, et al. Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2015 Jun;21(6):1008–19. 
  • Ong S-Y, Truong H-T-T, Diong CP, Linn Y-C, Ho AY-L, Goh Y-T, et al. Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. BMC Hematol. 2015;15:8. 
  • Ong S-Y, Ng HY, Surendran S, Linn YC, Chen Y, Goh YT, et al. Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Vol. 169, British journal of haematology. England; 2015. p. 754–6. 
  • Fan X, Gay FPH, Ong S-Y, Ang JML, Chu PPY, Bari S, et al. Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. Cytotherapy. 2013 May;15(5):610–9.


Research Trials